Table of Contents

2019-2024 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Report (Status and Outlook)

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2014-2024
2.1.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Region
2.2 Benign Prostatic Hyperplasia (BPH) Treatment Segment by Type
2.2.1 Drugs
2.2.2 Invasive Procedures
2.2.3 Device
2.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2014-2019)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type (2014-2019)
2.4 Benign Prostatic Hyperplasia (BPH) Treatment Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Other
2.5 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2014-2019)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Application (2014-2019)

3 Global Benign Prostatic Hyperplasia (BPH) Treatment by Players
3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Players
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Players (2017-2019)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Players (2017-2019)
3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Benign Prostatic Hyperplasia (BPH) Treatment by Regions
4.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions
4.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth
4.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth
4.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth
4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth

5 Americas
5.1 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Countries
5.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
5.3 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Countries
6.2 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
6.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment by Countries
7.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment by Countries
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast
10.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast (2019-2024)
10.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Regions
10.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Regions (2019-2024)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Type
10.8 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Application

11 Key Players Analysis
11.1 Astellas Pharma
11.1.1 Company Details
11.1.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.1.4 Main Business Overview
11.1.5 Astellas Pharma News
11.2 Eli Lilly
11.2.1 Company Details
11.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.2.4 Main Business Overview
11.2.5 Eli Lilly News
11.3 GlaxoSmithKline
11.3.1 Company Details
11.3.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.3.4 Main Business Overview
11.3.5 GlaxoSmithKline News
11.4 Sanofi
11.4.1 Company Details
11.4.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.4.4 Main Business Overview
11.4.5 Sanofi News
11.5 Novartis
11.5.1 Company Details
11.5.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.5.3 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.5.4 Main Business Overview
11.5.5 Novartis News
11.6 Teva
11.6.1 Company Details
11.6.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.6.3 Teva Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.6.4 Main Business Overview
11.6.5 Teva News
11.7 Boston Scientific
11.7.1 Company Details
11.7.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.7.3 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.7.4 Main Business Overview
11.7.5 Boston Scientific News
11.8 NxThera, Inc.(Rezum)
11.8.1 Company Details
11.8.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.8.3 NxThera, Inc.(Rezum) Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.8.4 Main Business Overview
11.8.5 NxThera, Inc.(Rezum) News
11.9 NeoTract, Inc.(UroLift)
11.9.1 Company Details
11.9.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.9.3 NeoTract, Inc.(UroLift) Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.9.4 Main Business Overview
11.9.5 NeoTract, Inc.(UroLift) News

12 Research Findings and Conclusion